Overview
Basic Science:
-Germline and somatic genetic changes in breast cancer.
Translational:
-Identification and management of individuals and families with hereditary cancer risk.
-Communication of cancer risk information to individuals and families.
-Breast cancer prevention.
-Optimizing management of early breast cancer.
-Treatment of metastatic breast cancer
Clinically, Dr. Marcom works as a medical oncologist in the multidisciplinary breast cancer clinic. He participates in clinical trials investigating new chemotherapeutic and biologic treatments.
-Germline and somatic genetic changes in breast cancer.
Translational:
-Identification and management of individuals and families with hereditary cancer risk.
-Communication of cancer risk information to individuals and families.
-Breast cancer prevention.
-Optimizing management of early breast cancer.
-Treatment of metastatic breast cancer
Clinically, Dr. Marcom works as a medical oncologist in the multidisciplinary breast cancer clinic. He participates in clinical trials investigating new chemotherapeutic and biologic treatments.
Current Appointments & Affiliations
Adjunct Professor in the Department of Medicine
·
2021 - Present
Medicine, Medical Oncology,
Medicine
Member of the Duke Cancer Institute
·
1989 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
A Phase I Trial of Alpelisib Combined With Capecitabine in Patients With HER2-Negative Metastatic Breast Cancer.
Journal Article Clin Breast Cancer · December 2024 BACKGROUND: Alpelisib is an oral α-specific class I PI3K inhibitor approved in combination with fulvestrant for the treatment of PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) metastatic breast can ... Full text Link to item CiteAdjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT.
Journal Article J Clin Oncol · November 2024 PURPOSE: Long-term outcomes of patients with stage I human epidermal growth factor receptor 2 (HER2)-positive breast cancer receiving adjuvant trastuzumab emtansine (T-DM1) remain undefined, and prognostic predictors represent an unmet need. METHODS: In th ... Full text Link to item CiteIdentifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes.
Journal Article Breast Cancer Res Treat · November 2023 PURPOSE: A 3-biomarker homologous recombination deficiency (HRD) score is a key component of a currently FDA-approved companion diagnostic assay to identify HRD in patients with ovarian cancer using a threshold score of ≥ 42, though recent studies have exp ... Full text Link to item CiteRecent Grants
TBCRC 041 Randomized Phase II Trial to Evaluate Alisertib Alone or Combined with Fulvestrant in Women with Advanced, Hormone-Receptor Positive (HR+) Breast Cancer
Clinical TrialPrincipal Investigator · Awarded by Mayo Clinic · 2019 - 2025Kastan Gray Foundation Project
ResearchResearcher · Awarded by Gray Foundation · 2017 - 2024TBCRC48 A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients with Germline or Somatic Mutations in DNA Repair Genes "Olaparib Expanded"
Clinical TrialPrincipal Investigator · Awarded by Johns Hopkins University · 2018 - 2023View All Grants
Education, Training & Certifications
Baylor University ·
1989
M.D.